Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 6—June 2005
Letter

Diversification in Salmonella Typhimurium DT104

On This Page
Article Metrics
11
citations of this article
EID Journal Metrics on Scopus

Cite This Article

To the Editor: Multidrug-resistant (MDR) Salmonella Typhimurium definitive phage type (DT) 104 with chromosomally encoded resistance to ampicillin, chloramphenicol, streptomycin/spectinomycin, sulfonamides, and tetracyclines (ACSSpSuT) was first identified and characterized in the United Kingdom in the early 1990s (1). MDR DT104 has subsequently caused numerous outbreaks throughout the world (1). The organism is characterized by a distinctive Xba I-generated pulsed-field profile (PFP), designated Xtm 1 (2), carriage of the 90-kb S. Typhimurium serovar-specific plasmid (SSP), and presence of the 43-kb Salmonella genomic island 1 (SGI 1), which is composed of integrons containing, respectively, the ASu (blaCARB-2 and sul1) and SSp (aadA2) genes, with intervening plasmid-derived genes coding for chloramphenicol/florfenicol (cmlA) and tetracycline resistance (tetG) (1,3,4). The same genetic characteristics have been observed in MDR strains of the closely related DTs 12 and 104b (5) and in some strains of phage type U302 (4). All isolates of MDR DT104 ACSSpSuT contain the same gene cassettes irrespective of source or country of origin. Although MDR DT104 has declined during the last 5 years, the organism remains the most common MDR Salmonella in the United Kingdom and many other European countries (6).

Since 1998, MDR DT104 has undergone changes in both resistance spectrum and genetic structure. In the United Kingdom, outbreaks of MDR DT104 have been caused by new subclones with additional resistance to trimethoprim (Tm) (R-type ACSSpSuTTm) (7), by clones with decreased susceptibility to ciprofloxacin (CpL) (R-type ACSSpSuTCpL) (1), and by strains of R-type SSpSu. In 2002, an outbreak of MDR DT104 ACSSpSuTTm with >200 cases was recognized (7). The outbreak strain was characterized by 3 plasmids of 6.8, 3.0, and 1.5 kb. The 6.8-kb plasmid coded for resistance to sulfonamides and trimethoprim, with trimethoprim resistance being mediated by dhfr1b. The outbreak strain lacked the S. Typhimurium SSP and was negative by polymerase chain reaction (PCR) for a 437-bp internal fragment of the Salmonella plasmid virulence (spv)C gene. The absence of the SSP was reflected in the PFP, which was identical to Xtm 1 but lacked a fragment of ≈90 kb that corresponds to the presence of the SSP (4). A strain of R-type ACSSpSuT that also lacked the SSP and with a PFP indistinguishable from that of the ACSSpSuTTm strain caused a simultaneous outbreak with >40 cases (7). This strain was also characterized by 2 plasmids of 3.0 and 1.5 kb but did not possess the 6.8-kb sulfonamide-trimethoprim resistance plasmid.

Decreased susceptibility to ciprofloxacin coupled with resistance to nalidixic acid (Nx) was first reported in MDR DT104 in 1996 in the United Kingdom (1). Four mutations in gyrA, each giving rise to resistance to Nx/CpL, were subsequently identified in MDR DT104. The most common mutation was aspartate (Asp)-87 to asparagine (AAC) and involved a change from aspartate (GAC) to AAC. An identical mutation was identified in a MDR DT104 strain responsible for an outbreak in Denmark in 1998 (8). In 1999, an Asp-87 to glycine mutation was identified in a CpL MDR DT104 strain responsible for a major outbreak in northwestern England (1). Subsequently, >500 sporadic MDR DT104 infections in the United Kingdom have involved strains with CpL.

In 2004, 2 simultaneous outbreaks of DT104 were recorded in the United Kingdom in which the strains were of R-type SSpSu, 1 involving >100 cases and 1 involving >50 cases. Isolates were characterized by pulsed-field gel electrophoresis coupled with plasmid profile analysis. Resistance genes were identified by using PCR with primers specific for blaTEM (A), blaCARB-2, cmlA, catI (C), catIII (C), aadA2, sul1, and tetG (4). Testing for SGI1 was conducted by using primers U7-L12 and LJ-R1 for the left junction and primers 104-RJ and 104-D for the right junction (9). All isolates exhibited the Xtm 1 PFP, but strains from the 2 outbreaks could be differentiated by the presence or absence of an additional plasmid of ≈3 kb. By using PCR, all isolates possessed aadA2 and sul1 but were negative for blaTEM,blaCARB-2, cmlA, catI, catIII, and tetG. Similarly, all strains were positive for the left junction of SGI1. These results indicate that the SGI1 was in the same chromosomal location as for DT104 ACSSpSuT but was lacking the right junction.

These findings demonstrate that evolutionary changes have occurred involving both loss and acquisition of drug resistance genes, the development of chromosomal mutations conferring resistance to Nx/CpL, and in certain subclones, the loss of the SSP. None of these changes has altered the virulence of the organism, with bloodstream invasion in only 1.6% of 408 cases in the United Kingdom. These findings contrast with those in the United States, where MDR nontyphoidal Salmonella have been associated with excessive numbers of bloodstream infections (10).

All facets of the organism should be explored for epidemiologic investigations. These should include phage type, antibiogram, plasmid profile, and PFP, coupled with the identification of resistance genes and integrons, and, when appropriate, the characterization of mutations conferring resistance to quinolone antimicrobial agents.

These studies were in part supported by a grant from the Department for Environment, Foods and Rural Affairs, reference V02136.

Top

John Threlfall*Comments to Author , Katie L. Hopkins*, and Linda R. Ward*
Author affiliations: *Health Protection Agency, Centre for Infections, London, United Kingdom

Top

References

  1. Threlfall  EJ. Epidemic Salmonella typhimurium DT104 - a truly international epidemic clone. J Antimicrob Chemother. 2000;46:710. DOIPubMedGoogle Scholar
  2. Lawson  AJ, Desai  M, O'Brien  SJ, Davies  RH, Ward  LR, Threlfall  EJ. Molecular characterisation of an outbreak strain of multiresistant Salmonella enterica serovar Typhimurium DT104 in the UK. Clin Microbiol Infect. 2004;10:1437. DOIPubMedGoogle Scholar
  3. Briggs  CE, Fratamico  PM. Molecular characterization of an antibiotic resistance gene cluster of Salmonella typhimurium DT104. Antimicrob Agents Chemother. 1999;43:8469.PubMedGoogle Scholar
  4. Walker  RA, Lindsay  E, Woodward  MJ, Ward  LR, Threlfall  EJ. Variation in clonality and antibiotic resistance genes among multiresistant Salmonella enterica serotype typhimurium phage type U302 (MR U302) from humans, animals and foods. Microb Drug Resist. 2001;7:1321. DOIPubMedGoogle Scholar
  5. Lawson  AJ, Dessama  MU, Ward  LR, Threlfall  EJ. Multiple resistant Salmonella enterica serovar Typhimurium DT12 and 120: a case of MR DT104 in disguise? Emerg Infect Dis. 2002;8:4346.PubMedGoogle Scholar
  6. Threlfall  EJ, Fisher  IST, Berghold  C, Gerner-Smidt  P, Tschape  H, Cormican  M, Antimicrobial drug resistance in Salmonella enterica in Europe in 2000: results of international multi-centre surveillance. Eurosurveillance. 2003;8:415.PubMedGoogle Scholar
  7. Threlfall  EJ, Hampton  MD, Chart  H, Hopkins  K, Ward  LR, Tebbutt  G. Emergence of new subclones of multiresistant S. typhimurium DT104 possibly associated with poultry. Vet Rec. 2004;154:8990. DOIPubMedGoogle Scholar
  8. Mølbak  K, Baggesen  DL, Aarestrup  FM, Ebbesen  JM. An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype Typhimurium DT104. N Engl J Med. 1999;341:14205. DOIPubMedGoogle Scholar
  9. Boyd  D, Cloeckaert  A, Chaslus-Dancla  E, Mulvey  MR. Characterisation of variant Salmonella genomic island 1 multidrug resistance regions from serovars Typhimurium DT104 and Agona. Antimicrob Agents Chemother. 2002;46:171422. DOIPubMedGoogle Scholar
  10. Varma  JK, Mølbak  K, Barrett  TJ, Jones  TK. Antimicrobial-resistant nontyphoidal Salmonella is associated with excess bloodstream infections and hospitalizations. J Infect Dis. 2005;191:55461. DOIPubMedGoogle Scholar

Top

Cite This Article

DOI: 10.3201/eid1106.050100

Related Links

Top

Table of Contents – Volume 11, Number 6—June 2005

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

John Threlfall, Health Protection Agency Centre for Infections, Laboratory of Enteric Pathogens, Specialist and Reference Microbiology Division, 61 Colindale Ave, London NW9 5HT, United Kingdom; fax: 44-208-905-9929

Send To

10000 character(s) remaining.

Top

Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external